


Claims

- 5 1. A pharmaceutical composition comprising compound (I)



and pharmaceutically acceptable salts thereof, in which the compound is present in solid particles in nanoparticulate form in admixture with one or more pharmaceutically acceptable carriers or excipients.

10

2. A pharmaceutical composition as claimed in claim 1 which further comprises HPMC present in less than 15% w/w.

15

3. A pharmaceutical composition as claimed in claim 1 or claim 2 which further comprises mannitol present in the range 30 to 45% w/w.

4. A pharmaceutical composition as claimed in any of claims 1 to 3 which further comprises sodium lauryl sulphate present in about 0.6% w/w.

20

5. A process for preparing a pharmaceutical composition according to any of claims 1 to 4 comprising wet milling a suspension of compound (I) in a mill having at least one chamber and agitation means, said chamber(s) and/or said agitation means comprising a lubricated nylon.

25

4. A method of treating a human or animal subject suffering from a condition which is mediated by COX-2 which comprises administering a pharmaceutical composition as defined in any of claims 1 to 4.

5. The use of a pharmaceutical composition as defined in any of claims 1 to 4 for the manufacture of a medicament for the treatment of a condition which is mediated by COX-2.